On 19th of May 2022, Attana announced an updated CE IVD marking for its AVATM SARS-CoV-2 IgG Immunoassay kit. This now includes capillary blood samples using Capitainer®qDBS which enables the technology to be used with self-sampling.
This follows on the announcement in February that Attana AB and Capitainer AB have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVATM system starting with COVID-19 immune profiling.
The combination of accurate and precise remote blood sampling with the unique Attana AVATM technology gives new possibilities to study antibody neutralization from patient samples. It provides laboratories with improved opportunities to perform immune profiling and monitoring of vaccine efficacy in broad patient populations.
